Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer: A randomized controlled trial of a 12-month exercise program

Polish Archives of Internal Medicine

Volumn 127, Issue 1, 2017, Pages 25-35

  Hojan, Katarzyna ^a   Kwiatkowska Borowczyk, Eliza ^a,b   Leporowska, Ewa ^a   Milecki, Piotr ^a,b  

^a GREATER POLAND CANCER CENTRE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cytokines; Exercise rehabilitation; Oncology; Physiotherapy; Radiation therapy

Indexed keywords

CYTOKINE; LUTEINIZING HORMONE DERIVATIVE; BIOLOGICAL MARKER;

AEROBIC CAPACITY; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER RISK; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CUMULATIVE TRAUMA DISORDER; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUESTIONNAIRE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY FATIGUE SCALE; FUNCTIONAL STATUS; FUNCTIONAL STATUS ASSESSMENT; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INTERMEDIATE RISK PATIENT; KINESIOTHERAPY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; MYALGIA; PROSTATE CANCER; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THERAPY EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WAIST HIP RATIO; BLOOD; CARDIAC MUSCLE; FATIGUE; HEART; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PARASITOLOGY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; ADULT; CANCER PATIENT; CANCER SCREENING; ELECTROCORTICOGRAPHY; EXERCISE; FUNCTIONAL ASSESSMENT; HEALTH PROGRAM; HOSPITAL PATIENT; LABORATORY TEST; PHYSICAL ACTIVITY; QUALITY OF LIFE;

AGED; BODY MASS INDEX; CYTOKINES; EXERCISE THERAPY; FATIGUE; HEART; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIUM; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85014127726     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3888     Document Type: Article

References (47)

1. Ferlay J, Soerjomataian I, Mathers C, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-386.
2. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2014;378:2104-2111.
3. Juloori A, Shah C, Stephans K, et al. Evolving paradigm of radiotherapy for high-risk prostate cancer: current consensus and continuing controversies. Prostate Cancer. 2016;2016:2 420 786.
4. Boxer RS, Kenny AM, Dowsett R, et al. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male. 2005;8:207-212.
5. Pirl WF, Siegel GI, Goode MJ, et al. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 2002;11:518-523.
6. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104:195-201.
7. Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008;102:44-47.
8. Lilleby W, Stensvold A, Dahl AA. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer. Acta Oncol. 2016;55:807-813.
9. Latorzeff I, Ploussard G, Guillotreau J, et al. Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology. Cancer Radiother. 2016;20:405-410.
10. Kohutek ZA, Weg ES, Pei X, et al. Long-term impact of androgen-deprivation therapy on cardiovascular morbidity after radiotherapy for clinically localized prostate cancer. Urology. 2016;87:146-152.
11. Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;29:e107 516.
12. Van Tassell BW, Raleigh JM, Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep. 2015;12:33-41.
13. Kanda T, Takahashi T Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004;45:183-193.
14. Ridker PM, Rifai N, Pfeffer M, et al, for the Cholesterol And Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-2153.
15. Myers J, McAuley P, Lavie CJ, et al. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc Dis. 2015;57:306-314.
16. Conn VS, Hafdahl AR, Porock DC, et al. A meta-analysis of exercise interventions among people treated for cancer. Support Care Cancer. 2006;14:699-712.
17. Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients: a systematic review of randomized controlled trials. Support. Care Cancer. 2012;20:221-233.
18. Gardner JR, Livingston PM, Fraser SF Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 2014;32:335-346.
19. Galvão DA, Spry N, Denham J, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65:856-864.
20. Windsor PM, Nicol KF, Potter J. A randomised, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localised prostate carcinoma. Cancer. 2004;101:550-557.
21. Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an american cancer society guide for informed choices. CA Cancer J Clin. 2006;56:323-353.
22. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106-2131.
23. Landers J. Maximums based on reps. Nat Strength Cond Assoc J. 1985;6:60-61.
24. Godin G, Shephard RJ. Godin Leisure-Time Exercise Questionnaire. Med Sci Sports Exerc. 1997;29:36-38.
25. Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15:116-122.
26. Schmidt K, Vogt L, Thiel C, et al. Validity of the six-minute walk test in cancer patients. Int J sports Med. 2013;34:631-636.
27. American Thoracic Society. American Thoracic Society statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
28. Ross RM, Murthy JN, Wollak ID, et al. The six minute walk test accurately estimates mean peak oxygen uptake. BMC Pulm Med. 2010;10:31.
29. Solway S, Brooks D, Lacasse Y, et al. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest. 2001;119:256-270.
30. Muszalik M, Kedziora-Kornatowska K, Kornatowski T. Functional assessment and health-related quality of life (HRQOL) of elderly patients on the basis of the functional assessment of chronic illness therapy (FACIT)-F questionnaire. Arch Gerontol Geriatr. 2009;49:404-408.
31. Cella D F, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
32. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Int. 1993;85:365-376.
33. Van Andel G, Bottomley A, Fosså SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418-2424.
34. Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, et al. Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study. Eur J Phys Rehabil Med. 2016;52:489-501.
35. Starkie R, Ostrowski SR, Jauffred S, et al. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003;17:884-886.
36. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 2002;162:1286-1292.
37. Pearson TA, Mensah GA, Alexander RW, et al. Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association Circulation. 2003;107:499-511.
38. Myint PK, Kwok CS, Luben RN, et al. Body fat percentage, body mass index and waist-to-hip ratio as predictors of mortality and cardiovascular disease. Heart. 2014;100:1613-1619.
39. Cormie P, Galvão DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115:256-266.
40. Leisegang K, Bouic PJ, Henkel RR. Metabolic syndrome is associated with increased seminal inflammatory cytokines and reproductive dysfunction in a case-controlled male cohort. Am J Reprod Immunol. 2016;76:155-163.
41. Christensen E, Pintilie M, Evans Kr, et al. longitudinal cytokine expression during imrt for prostate cancer and acute treatment toxicity. Clin Cancer Res. 2009;15:5576-5583.
42. Bower JE, Ganz PA, Tao ML, et al. Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer. Clin Cancer Res. 2009;15:5534-5540.
43. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98:1154-1162.
44. Farinha JB, Steckling FM, Stefanello ST, et al. Response of oxidative stress and inflammatory biomarkers to a 12-week aerobic exercise training in women with metabolic syndrome. Sports Med Open. 2015;1:3.
45. Van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88:3005-3010.
46. Dahn JR, Penedo FJ, Molton I, et al. Physical activity and sexual functioning after radiotherapy for prostate cancer: beneficial effects for patients undergoing external beam radiotherapy. Urology. 2005;65:953-958.
47. Hayes BD, Brady L, Pollak MN, et al. Exercise and prostate cancer: evidence and proposed mechanisms for disease modification. Cancer Epidemiol Biomarkers Prev. 2016;25:1281-1288.